

Left atrial volume index as a predictor of events in acute coronary

Le volume de l'oreillette gauche indexé comme prédicteur d'événements dans le syndrome coronarien aigu

S. Antit¹, Y. Draoui², A. Mrabet¹, H. Ben Jemaa², E. Boussabeh¹, L. Zakhama¹

1. Interior Security Forces Hospital, Department of Cardiology, Marsa, Tunisia
2. Hospital Charles Nicolle, Department of cardiology, Tunis, Tunisia

SUMMARY

Introduction : According to some international studies, patients with acute coronary syndrome (ACS) and increased left atrial volume index (LAVi) have worse long-term prognosis. The aim of our study is to assess the role of LAVi as a predictor of major adverse clinical events (MACE) after ACS.

Methods: This was a prospective mono-centric observational study conducted between January 2019 and September 2022, and included patients with ACS. The maximal LA volume was measured from the apical four and two chambers views by using the biplane area length method. The primary clinical endpoint was the occurrence of MACE.

Results: The study included 139 patients with a mean age 59.8 years. Our population was predominantly male, with 117 men (84.2%). Mean LAVi was 34.76 ± 10 ml/m².

With an average follow-up time of 25 months, MACE was noted in 34.5% of cases. On multivariate analysis, a higher LAVi [OR = 1.139 (1.028 1.261), P = 0.047], was a predictor of MACE. A cut off of LAVi ≥ 33.15 ml/m², predicted MACE with area under curve (AUC) 0.600 (95% CI 0.490 0.701) with a sensitivity and specificity of 60.4% and 53.8% respectively in ROC curve analysis.

Conclusion: Increased LAVi is an independent predictor of outcome in patients with ACS. Thus, LAVi measurement should be incorporated as routine to the assessment of patients diagnosed with ACS.

MOTS-CLÉS

Acute coronary syndrome, major adverse cardiac events, echocardiography, left atrium volume

RÉSUMÉ

Introduction : Selon certaines études internationales, les patients se présentant pour syndrome coronarien aigu (SCA) et ayant une augmentation du volume de l'oreillette gauche (VOGi) ont un pronostic à long terme plus péjoratif. L'objectif de notre étude est d'évaluer le rôle du VOGi comme prédicteur d'événements cliniques indésirables majeurs (MACE) après un SCA.

Méthodes : Il s'agit d'une étude longitudinale monocentrique prospective réalisée entre janvier 2019 et septembre 2022, incluant des patients atteints de SCA. Le VOGi a été mesuré à partir des incidences apicales quatre et deux chambres en utilisant la méthode de la longueur de la surface biplan. Le critère d'évaluation clinique principal était la survenue de MACE.

Résultats : L'étude a inclus 139 patients avec une moyenne d'âge de 59,8 ans. Notre population était majoritairement masculine, avec 117 hommes (84,2%). Le VOGi moyen était de $34,76 \pm 10$ ml/m². Des MACE ont été notés dans 34,5 % des cas au cours d'un suivi moyen de 25 mois. En analyse multivariée, un VOGi élevé [OR = 1,139 (1,028 1,261), P = 0,047] était prédicteur significatif de MACE. Un seuil de VOGi $\geq 33,15$ ml/m² prédisait les MACE avec une aire sous la courbe (AUC) de 0,600 (IC à 95 % 0,490-0,701) avec une sensibilité et une spécificité de 60,4 % et 53,8 % respectivement.

Conclusion : L'augmentation du VOGi est un prédicteur indépendant de l'issue chez les patients atteints de SCA. Ainsi, la mesure du VOGi devrait être intégrée systématiquement.

KEYWORDS

Syndrome coronarien aigu, événements cardiaques indésirables majeurs, échocardiographie, volume de l'oreillette gauche

Correspondance

S. Antit

Background

Left atrial (LA) measurements have emerged, in recent years, as the focus of cardiovascular research. LA volume and size have close association with left ventricular (LV) systolic and diastolic function. After acute coronary syndrome (ACS) diastolic function assessed by Doppler echocardiography provides important prognostic information. However, Doppler variables are affected by multiple factors and may change rapidly. In contrast, left atrial volume is less influenced by acute changes and reflects subacute or chronic diastolic function.

The aim of our study is to assess the role of Left atrial volume index (LAVi) as a predictor of major adverse clinical events (MACE) after acute coronary syndrome.

METHODS

Study population

This was a prospective mono-centric observational study conducted between January 2019 and September 2022, in the Cardiology Department of the Internal Security Forces Hospital of Marsa, Tunisia and included 139 patients with acute coronary syndrome.

Inclusion criteria

We included all patients hospitalized for ST segment elevation myocardial infraction (STEMI), no ST segment elevation myocardial infraction (NSTEMI) or unstable angina with an age ≥ 18 years, stable hemodynamic state and Left ventricular

ejection fraction (LVEF) $\geq 40\%$.

Exclusion criteria

We excluded all patients with atrial fibrillation (AF), infiltrative or hypertrophic, constrictive pericarditis, and significant valvular heart disease.


Data collection

Baseline clinical characteristics, comorbidities, previous cardiovascular disease, diagnosis, ECG, biological data, echocardiographic data, coronary angiography results and treatment were collected.

All patients underwent transthoracic echocardiography (TTE) using a Philips EPIQ 7C with assessment of systolic function by measuring Simpson LVEF and global longitudinal strain. Diastolic function was assessed according to the American society of echocardiography (ASE) 2015 and 2016 guidelines (1,2).

The maximal LA volume was measured from the apical four chamber view by using the biplane area length method (from apical 4 and 2 chamber views, measurements obtained in end systole from the frame preceding mitral valve opening) (Figure 1). The average of LA volume thus measured was then corrected for body surface area to calculate LAV index (LAVi).

Normal LA size was defined as LAVi ≤ 34 ml/m², mild dilatation as 35-41 ml/m², moderate dilatation as 42-48 ml/m² and severe dilatation as >48 ml/m² (2).



Primary clinical endpoint

The primary clinical endpoint was the occurrence of MACE (myocardial infarction, hospitalization for heart failure, stroke and death).

Statistical analysis

The study data were analyzed using SPSS 22.0 software. Simple frequencies and relative frequencies (percentages) were calculated for the qualitative variables.

For comparisons of qualitative variables between two or more groups, we used Pearson's Chi 2 test or Fisher's exact test, where the number of participants was less than 5.

For comparisons of quantitative variables, we used Student's t-test and analysis of variance (ANOVA) to compare means in case of a normal distribution, and the Mann Whitney and Kruskal Wallis tests in if it is a non-Gaussian distribution.

The determination of predictive factors of MACE after ACS was carried out in two stages. The first step was to perform a univariate analysis to test the significance of each variable, independently of the other variables. The second step was to perform a multivariate analysis to look for independent predictive factors of MACE after ACS. This was carried out by Cox regression using the stepwise method, with the inclusion of all factors for which the p values were < 0.1 in the univariate analysis. In all statistical tests, a P value of <0,05 was considered statistically significant.

RESULTS

Baseline characteristics of the study population

The study included 139 patients with a mean age 59.8 years (range 28 - 92 years). Our population was predominantly male, with 117 men (84.2%) and 22 women (15.8%), giving a sex ratio of 5.3.

Cardiovascular risk factors were dominated by smoking in 70.5% of cases, followed by type II diabetes in 56.8% and arterial hypertension in 53%. As regards previous history, peripheral artery disease (PAD) was noted in 10.8% of patients. 5% of patients had chronic kidney disease (CKD), 24.5% of the population had an acute coronary syndrome (ACS) history and 2.9% had an episode of heart failure (HF).

Unstable angina was diagnosed in 55.4% of cases, NSTEMI in 35.3% and STEMI in 9.4%. The mean GRACE score was 120 ± 32 with a mean troponin peak of 3540.52.

Echocardiographic parameters are shown in table 1.

Table 1. Echocardiographic characteristics of the population

	Mean	Standard deviation	Minimum	Maximum
LVEF %	60,5	7	40	78
GLS %	-19,7	3,3	-8	-28
LVEDD mm	51	5	39,2	63,8
LV EDV mL	96,3	27,5	44	162
LV ESV mL	41,2	20	12	127
LVMI g/m ²	99,4	26,5	49	234
Mitral E wave cm/s	67,8	17,5	36	122
E/A	1	0,35	0,4	2,4
E/E'	7,5	2,7	4	13,4
sPAP mmHg	29,8	8,9	15	70
Vmax TR m/s	2,4	0,39	1,19	3,6
LAVi mL/m ²	34,7	10	14	81

LAVi: Left atrial volume index; LV EDV: Left ventricular end diastolic volume; LVEDD: left ventricular end diastolic diameter; LVEF: Left ventricular ejection fraction; LV ESV: Left ventricular end systolic volume; LVMI: left ventricular mass index; LVEF: Left ventricular ejection fraction; LVMI: Left ventricular mass index; GLS: Global longitudinal strain; sPAP: systolic pulmonary artery pressure; V max TR: peak velocity (Vmax) of the tricuspid regurgitation

Angiography showed a single vessel disease in 43.9% of cases, a double vessel coronary artery disease in 20.9% of cases and multivessel disease in 26.6% of patients. A stenosis of the left main was noted in 5.8% of cases. A tight stenosis of the LAD was found in 71% of patients and a lesion of the circumflex in 51% of cases. The right coronary artery was involved in 42.4% of cases. 71.9% of patients received percutaneous treatment and 6.5% underwent coronary artery bypass grafting.

With an average follow-up time of 25 months, MACE was noted in 34.5% of cases, with non-fatal MI in 26.6% and death from any cause in 2.2% of patients.

Baseline and echocardiographic characteristics according to left atrial enlargement by volume index

Hypertension, PAD and CKD in dialysis were associated with moderate to severe enlargement of the left atrium. Patients with greater LA enlargement had higher LV mass index, mitral E wave velocity, E/E' ratio and systolic pulmonary artery pressure (sPAP). Worse LV diastolic dysfunction was associated with greater LA enlargement (Table 2).

Table 2. Different types of AVSD and Patient demographic data in our study

	Normal and Mild LA size enlargement n=113	Moderate to severe LA size enlargement n=26	P
Baseline characteristics			
Age, years	59±10	63 ±9	0,064
Male gender	85%	76,9%	0,261
Hypertension	47,8%	76,9%	0,007
Diabetes	54,8%	65,3%	0,329
Current smoker	72,5%	61,5%	0,266
PAD	7,9%	23%	0,025
CKD	4,6%	7,6%	0,492
Dialysis	0%	3,8%	0,036
ACS history	24,7%	23%	0,856
HF	1,7%	7,6%	0,103
Diagnosis			
STEMI	10,6%	3,2%	0,250
NSTEMI	37,1%	26%	0,250
Unstable angina	52,2%	62%	0,250
Culprit vessel			
Left main	5%	7,6%	0,638
LAD	69,6%	80,7	0,256
Circumflex	54,4%	38,4%	0,141
Right coronary	46,4%	26,9%	0,07
Multivessel disease	30,6%	11,5%	0,06
Grace score	121±32	116±31	0,557
Biomarkers			
Troponines (pg/ml)	4255±11971	335±969	0,105
Echocardiographic characteristics			
LVEDD, mm	51±5	52±5	0,192
LVMI, g/m ²	96,5±23,8	112±33	0,006
LVEF, %	60,6±7	60,2±7,5	0,79
Mitral E wave, cm/s	66,6±17,5	75±16	0,021
Mitral E/A	0,96±0,3	1,17±0,4	0,007
Mean mitral E/E'	7,6±2	9,1±2,7	0,092
PAPs	28±6	35±11	0,0001
GLS,%	19,5±3,3	20,8±3	0,08
LV diastolic function			
Grade I	89,1%	47,6%	0,0001
Grade II	6%	23%	0,0001
Grade III	0%	9,5%	0,0001

Data shown as numbers (%) or mean and standard deviation (SD). ACS history: acute coronary syndrome history; CKD: chronic kidney disease; GLS: global longitudinal strain; HF: Heart failure; LAD: Left anterior descending artery; LVEDD: left ventricular end diastolic diameter; LVEF: Left ventricular ejection fraction; LVMI: left ventricular mass index; NSTEMI: no ST segment elevation acute myocardial infarction; PAD: peripheral artery disease; PAPs: systolic pulmonary artery pressure; STEMI: ST elevation acute myocardial infarction; LV: left ventricular

Predictive factors for MACE

As shown in Table 3, on univariate analysis, CKD [OR = 5.1 (0.96-27.7), P = 0.035], acute coronary syndrome history [OR = 3.32 (1.49-7.3), p = 0.003], LAD stenosis [OR = 2.62 (1.09-6.3), P = 0.027] and higher LAVi [P = 0.014] were significantly associated with the occurrence of MACE.

Table 3. Predictive factors for MACE in in univariate analysis

	No MACE	MACE	Odds ratio	P
Age, years	59,5±10,2	60,4±11,4	-	0,64
Male gender	64,9%	35%	0,86(0,32-1,29)	0,77
Hypertension	51,6%	56,2%	0,60(0,59-2,43)	0,605
Diabetes	52,7%	64,5%	1,63(0,79-3,35)	0,180
Current smoker	73,6%	64,5%	0,65(0,3-1,38)	0,266
PAD	7,7%	16,6%	2,4(0,81-7,08)	0,105
CKD	2,2%	10,4%	5,17(0,96-27,7)	0,035
Dialysis	0%	2,1%	-	0,340
ACS history	16,5%	39,6%	3,32(1,49-7,3)	0,003
HF history	1,1%	6,2%	6(0,60-59,3)	0,084
Diagnosis				
STEMI	9,8%%	8,3%	-	0,092
NSTEMI	35,1%	35,4%	-	0,092
Unstable angina	54,9%	56,2%	-	0,092
Culprit vessel				
Left main	4,4%	8,3%	1,97(0,47-8,2)	0,343
LAD	65,5%	83,3%	2,62(1,09-6,3)	0,027
Circumflex	47,7%	58,3%	1,53(0,75-3,1)	0,237
Right coronary	40%	47,9%	1,38(0,68-2,79)	0,371
Multivessel disease	28,1%	30%	1,77(0,81-3,83)	0,146
Biomarkers				
Troponines (pg/ml)	4255±11971	335±969	-	0,266
Echocardiographic characteristics				
LVEF, %	60,8±7	60±7	-	0,484
GLS,%	19,9±3	19,4±4	-	0,374
LAVi, ml/m ²	33,1±8,7	37,8±13,1	-	0,014

Data shown as numbers (%) or mean and standard deviation (SD). ACS history: acute coronary syndrome history; CKD: chronic kidney disease; GLS: global longitudinal strain; HF: Heart failure; LAD: Left anterior descending artery; LVEF: Left ventricular ejection fraction; NSTEMI: no ST segment elevation acute myocardial infarction; PAD: peripheral artery disease; STEMI: ST elevation acute myocardial infarction; LAVi: left atrial volume index.

On multivariate analysis, the presence of CKD [OR = 5.338 (1.817-15.683), P = 0.045], acute coronary syndrome history [OR = 3.32 (1.49-7.3), P = 0.002] and higher LAVi [OR = 1.139 (1.028-1.261), P = 0.047], were the only significant predictors of MACE (Table 4).

Table 4. Multivariate analysis with confounding variables

Table 1. Multivariate analysis with confounding variables						
	B	E.S	P value	95% CI for EXP(B)		
				Lower	Upper	
CKD	-1,833	,912	,045	,160	,027	,956
ACS history	-1,346	,430	,002	,260	,112	,604
LAVi	,038	,019	,047	1,039	1,000	1,079

ACS history: acute coronary syndrome history; CKD: chronic kidney disease; LAVi: left atrial volume index.

Analysis of receiver operating characteristics curve (ROC) as shown in Figure 2; LAVi demonstrated that a cut off 33.15 ml/m², predicted MACE with area under curve (AUC) 0.600 (95% CI 0.490 0.701) with a sensitivity and specificity of 60.4% and 53.8% respectively.




Figure 2. Receiver- operating characteristics curve (ROC) for LAVi

DISCUSSION

In this study, patients with greater LA enlargement had higher LV mass index, mitral E wave velocity, E/E' ratio and sPAP. Worse LV diastolic dysfunction was associated with greater LA enlargement. Likewise, Hypertension, PAD and CKD in dialysis were associated with moderate to severe enlargement of the left atrium. Increased LAVi is an independent predictor of outcome in patients with ACS. A cut-off of LAVi ≥ 33.15 ml/m², predicted MACE. A Tunisian study included 50 hypertensive patients compared to 50 healthy controls, Antit et al. concluded that hypertension was associated with an increase of LAVi, ventricular hypertrophy and the degree of diastolic dysfunction (3).

Hence the interest in assessing LAVi as an index of long-term diastolic dysfunction. In fact, during ventricular diastole, the left atrium is directly exposed to LV pressures through the open mitral valve. Doppler indices of diastolic function have been shown to predict morbidity and mortality in patients with acute myocardial infarction (AMI) but it provides an instantaneous assessment of diastolic function, therefore LA volume is less sensitive to acute

variations, reflecting subacute or chronic changes in diastolic function, would predict long-term outcome after AMI and might be superior in this respect to conventional Doppler (4–6).

In a study including 1128 patients, Shih et al. showed that LA volume parameters can identify LVFP >15 mm Hg and differentiate among patterns of ventricular diastolic dysfunction and offer better performance than even tissue Doppler (7).

Tsang et al. showed, in a study including 140 patients, that LA volume was found to correlate positively with LV end-diastolic and end-systolic dimensions, LV mass, diastolic function grade, tissue Doppler E/E' tricuspid regurgitation velocity. LA volume expressed the severity of diastolic dysfunction and provided an index of cardiovascular risk and disease burden. In addition, an indexed OG volume >28 ml/m² was superior to the E/E' ratio for identifying diastolic dysfunction (8).

Assessment of the left atrium is based on a number of parameters, including the anteroposterior diameter of the left atrium obtained in the left parasternal long axis view, which remains limited due to the eccentric enlargement of the left atrium, which reduces its accuracy. Similarly, LA planimetry, which is widely used in daily practice, underestimates LA dilatation in the majority of cases (9).

Calculating the LA volume therefore represents a more consistent determination of LA size as compared to diameter or area measurements and LA volume indexed to body surface area (LAVi) is the recommended method for LA size quantification (9). In our study, indexed LA volume was the reference method for detecting LA dilatation using the formula $\text{area} \times \text{length } 0.8 \times A1 \times A2/L$ in apical 4-chamber and 2 chamber.

In the present study, with an average follow-up time of 25 months, MACE was noted in 34.5% of cases, with non-fatal AMI in 26.6% and death from any cause in 2.2% of patients.

The presence of CKD [OR = 5.338 (1.817 15.683), P = 0.045], acute coronary syndrome history [OR = 3.32 (1.49 7.3), P=0.002] and higher LAVi [OR = 1.139 (1.028 1.261), P = 0.047], were the only significant predictors of MACE.

The impact of CKD and ACS history on MACE in patients hospitalized for ACS is well defined (10). In a study including 3281 patients with CKD, Hashimoto et al.

showed that three-year MACE significantly deteriorated from 15.8% in no CKD through 38.2% in moderate CKD to 57.9% in severe CKD, respectively ($P < 0.0001$) (11).

The left atrium is a major prognostic parameter not only in the general population but also in coronary patients.

Several studies have shown that increased LAVi is a powerful predictor of mortality after AMI and provides prognostic information. In a series including 314 patients, Moller et al. showed that LA volume index was associated with a hazard ratio of 1.05 for a 1 mL/m² increase (95% CI 1.03 to 1.06, $P = 0.0001$) (12). These results were found in our study with an HR of 1.039 for 1 mL/m² increase in LAVi.

In a Malaysian study, including 75 patients who were admitted with ACS stratified into 2 arms: normal LAVi and increased LAVi, with a cut off value of 28 mL/m², Gunasekaran et al. showed that Patients with increased LAVi had significantly more MACEs, $p = 0.021$ (13).

A Portuguese study including 299 patients with STEMI, Cordeiro et al. demonstrated that severe LA enlargement by LAVi was an independent predictor of all-cause mortality (HR: 11.153; 95% CI: 1.924-64.642, $p = 0.007$) and cardiovascular endpoints during follow-up [(HR: 4.351; 95% CI: 1.919-9.862, $p < 0.001$)] (14).

In prospective cohort of the "Solar Registry" carried out at Hospital Sao Lucas, Brazil, including 171 patients disrupted into two groups according to LAVi values : normal LAVi ≤ 32 mL/m² and increased LAVi > 32 mL/m², Secondo Junior et al. showed the increase in the relative risk (RR) for combined outcome in 365 days in patients with increased LAVi (RR = 3.459; 95% CI = 1.54-7.73) as compared with the group of patients with normal LAVi (15). Similarly, Salehi et al., in a cohort conducted on 100 patients admitted with ACS, demonstrated that mortality (27.3%) in patients with atrium index > 32 mL /m² is more than cases with lower atrium index (1.3%) ($p = 0.001$) (16).

A Meta-analysis included a total of 2,705 patients from 11 cohort studies with a mean follow-up 18.7 ± 9.8 months. Ahmeti et al. concluded that patients with low LAVi (< 32 mL/m²) had low risk for MACE (15.9% vs. 33.7%; $p < 0.01$), long-term all-cause mortality (9.14% vs. 18.1%; $p < 0.01$), short-term mortality (3.31% vs. 9.38%; $p = 0.02$) and lower hospitalization rate (11.6% vs. 25.5%; $p < 0.01$) compared to patients with increased LAVi (17).

Saklecha et al. showed in an Indian study that 190 patients hospitalized for ACS and divided in two groups (group 1 LAVi ≥ 32 mL/m² and group 2 LAVi < 32 mL/m²), major adverse cardiovascular events (MACE) at 30 days was significantly higher in group 1 (20.7 vs 6.3%, $P = 0.006$). ROC curve analysis for LAVi demonstrated that a cut off 33.35 mL/m² predicted 30 day MACE with Area under curve (AUC) 0.775 (95% CI 0.700 0.850); sensitivity and specificity of 86.7% and 61.4% (18).

This same cut-off was found in our study but with low sensibility and specificity. In fact, ROC curve analysis for LAVi found that a cut off 33.15 mL/m² predicted MACE with area under curve (AUC) 0.600 (95% CI 0.490 0.701) with a sensitivity and specificity of 60.4% and 53.8% respectively.

CONCLUSION

Increased LAVi is an independent predictor of outcome in patients with ACS. A cut-off of LAVi ≥ 33.15 mL/m², predicted MACE with a sensitivity and specificity of 60.4% and 53.8% respectively.

LA volume was associated with LV hypertrophy, diastolic function and filling pressures in patients with ACS. It provides additional information to other prognostic marker such as LVEF and it is easily obtained in echocardiography. Thus, LAVi measurement should be incorporated as routine to the assessment of patients diagnosed with ACS.

REFERENCES

1. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr.* 2016;29(4):277-314.
2. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr.* 2015;28(1):1-39.e14.

3. Antit S, Zakhama L, Amri A, Boussabeh E, Thameur M, Ben Youssef S. Assessment of left atrial mechanical function by two-dimensional echocardiography in hypertensive patients. *Tunis Med.* juill 2019;97(7):882-90.
4. Pritchett AM, Mahoney DW, Jacobsen SJ, Rodeheffer RJ, Karon BL, Redfield MM. Diastolic dysfunction and left atrial volume: a population-based study. *J Am Coll Cardiol.* 4 janv 2005;45(1):87-92.
5. Greenberg B, Chatterjee K, Parmley WW, Werner JA, Holly AN. The influence of left ventricular filling pressure on atrial contribution to cardiac output. *Am Heart J.* déc 1979;98(6):742-51.
6. Simek CL, Feldman MD, Haber HL, Wu CC, Jayaweera AR, Kaul S. Relationship between left ventricular wall thickness and left atrial size: Comparison with other measures of diastolic function. *J Am Soc Echocardiogr.* janv 1995;8(1):37-47.
7. Sh H, KIL, Kr C. Comparison of left atrial volume parameters in detecting left ventricular diastolic dysfunction versus tissue Doppler recordings. *Am J Cardiol [Internet].* 3 janv 2012 [cité 8 oct 2023];109(5). Disponible sur: <https://pubmed.ncbi.nlm.nih.gov/22152972/>
8. Tsang TSM, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. *Am J Cardiol.* 15 déc 2002;90(12):1284-9.
9. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. *J Am Soc Echocardiogr.* déc 2005;18(12):1440-63.
10. De Luca L, Paolucci L, Nusca A, Putini RL, Mangiacapra F, Natale E, et al. Current management and prognosis of patients with recurrent myocardial infarction. *Rev Cardiovasc Med.* 24 sept 2021;22(3):731-40.
11. Hashimoto Y, Ozaki Y, Kan S, Nakao K, Kimura K, Ako J, et al. Impact of Chronic Kidney Disease on In-Hospital and 3-Year Clinical Outcomes in Patients With Acute Myocardial Infarction Treated by Contemporary Percutaneous Coronary Intervention and Optimal Medical Therapy - Insights From the J-MINUET Study. *Circ J Off J Jpn Circ Soc.* 24 sept 2021;85(10):1710-8.
12. Moller JE, Hillis GS, Oh JK, Seward JB, Reeder GS, Wright RS, et al. Left atrial volume: a powerful predictor of survival after acute myocardial infarction. *Circulation.* 6 mai 2003;107(17):2207-12.
13. Gunasekaran R, Maskon O, Hassan HHC, Safian N, Sakthiswary R. Left atrial volume index is an independent predictor of major adverse cardiovascular events in acute coronary syndrome. *Can J Cardiol.* 2012;28(5):561-6.
14. Cordeiro F, Silva Mateus P, Leão S, Moz M, Trigo J, Ferreira C, et al. Left atrial volume index: Can it provide additional prognostic information in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention? *Rev Port Cardiol.* oct 2018;37(10):799-807.
15. Secundo Junior JA, Santos MAA, Faro GB de A, Soares CB, Silva AMP, Secundo PFC, et al. Left Atrial Volume Index and Prediction of Events in Acute Coronary Syndrome: Solar Registry. *Arq Bras Cardiol.* oct 2014;103(4):282-91.
16. Salehi R, Samadikhah J, Azarfarin R, Goldust M. Effect of left atrium volume on patients' prognosis following acute myocardial infarction. *Pak J Biol Sci PJBs.* 15 déc 2013;16(24):1936-42.
17. Ahmeti A, Bytyçi FS, Bielecka-Dabrowa A, Bytyçi I, Henein MY. Prognostic value of left atrial volume index in acute coronary syndrome: A systematic review and meta-analysis. *Clin Physiol Funct Imaging.* mars 2021;41(2):128-35.
18. Saklecha A, Kapoor A, Sahu A, Khanna R, Kumar S, Garg N, et al. Is Indexed Left Atrial Volume (LAVi) in Indian Patients with Acute Coronary Syndrome (ACS) Undergoing Revascularization a Predictor of Cardiovascular Outcomes? *Ann Card Anaesth.* 2022;25(1):19-25.
19. S G, Sa M, Cr A, Jd B, Pc P, Dw M, et al. Left atrial structure and function and clinical outcomes in the general population. *Eur Heart J [Internet].* janv 2013 [cité 9 oct 2023];34(4). Disponible sur: <https://pubmed.ncbi.nlm.nih.gov/22782941/>
20. K H, K N, M D, YY, J I, T N, et al. Prevalence, Determinants, and Prognostic Value of Left Atrial Dysfunction in Patients With Chronic Coronary Syndrome and Normal Left Ventricular Ejection Fraction. *Am J Cardiol [Internet].* 15 janv 2023 [cité 9 oct 2023];187. Disponible sur: <https://pubmed.ncbi.nlm.nih.gov/36459745/>